Core Viewpoint - The stock of LaiKai Pharmaceutical (02105) has seen a significant increase of over 5%, currently trading at 12.82 HKD, following the publication of promising clinical trial results for its drug Afuresertib in treating advanced breast cancer [1] Group 1: Clinical Trial Results - The international scientific journal Nature Communications published a study led by Professor Xu Binghe, indicating that the combination of Afuresertib and Fulvestrant shows encouraging anti-tumor activity and good safety profiles in patients with HR+HER2- advanced breast cancer [1] - The ongoing Phase III clinical trial AFFIRM-205 for LAE002 (Afuresertib) in combination with Fulvestrant is progressing well, with completion of patient enrollment expected by December 2025 [1] Group 2: Regulatory and Commercialization Plans - LaiKai Pharmaceutical plans to submit a new drug application to the China National Medical Products Administration in the first half of this year, following the announcement of top-line data [1] - In November 2025, LaiKai Pharmaceutical signed an exclusive licensing agreement with Qilu Pharmaceutical for the commercialization of LAE002 in China [1]
港股异动 | 来凯医药(02105)午前涨超5% LAE002临床研究成果登上《自然-通讯》杂志